The notices it replaced
- Reissues: PAR-18-941 Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional)
Replaced by PAR-25-286.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $578,327 in first-year total cost, median $289,164.
Most frequent study sections
- Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section[BNVT]1
- Special Emphasis Panel[ZRG1 ETTN-D (91)]1
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Real-time visualization and precision targeting in transcranial magnetic stimulation1R21MH126396-01 · under PAR-18-941 | NING, LIPENG | BRIGHAM AND WOMEN'S HOSPITAL, MA | $277,289 | ZRG1 |
| 2019 | Fabrication and testing of next generation cortical paddle leads for bidirectional neural interfaces1R21MH120810-01 · under PAR-18-941 | HAQUE, RAZI-ULSTARR, PHILIP ANDREW | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $301,038 | BNVT |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.